Technical Analysis for NKTX - Nkarta, Inc.

Grade Last Price % Change Price Change
C 11.40 -6.29% -0.77
NKTX closed down 6.29 percent on Monday, March 18, 2024, on 25 percent of normal volume.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Wide Bands Range Expansion 0.00%
Crossed Above 20 DMA Bullish -6.29%
Earnings Movers Other -6.29%
Wide Bands Range Expansion -6.29%
Gapped Up Strength -6.29%
Fell Below 20 DMA Bearish 0.18%
MACD Bearish Signal Line Cross Bearish 0.18%
Earnings Movers Other 0.18%
Wide Bands Range Expansion 0.18%

   Recent Intraday Alerts

Alert Time
Fell Below Previous Day's Low about 20 hours ago
Down 10% about 20 hours ago
Down 1 ATR about 20 hours ago
Down 5% about 20 hours ago
Down 3% about 20 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Biology Immune System Immunotherapy Cancer Treatment Tumor Lymphoma Gene Therapy Virotherapy Chimeric Antigen Receptor T Cell Natural Killer Cell Chimeric Antigen Receptor Therapies For Cancer Antigen CD19 Tumor Cell

Is NKTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 16.24
52 Week Low 1.28
Average Volume 2,184,222
200-Day Moving Average 4.59
50-Day Moving Average 10.54
20-Day Moving Average 12.15
10-Day Moving Average 13.34
Average True Range 1.21
RSI (14) 47.92
ADX 39.73
+DI 24.25
-DI 21.61
Chandelier Exit (Long, 3 ATRs) 12.60
Chandelier Exit (Short, 3 ATRs) 13.04
Upper Bollinger Bands 15.73
Lower Bollinger Band 8.57
Percent B (%b) 0.4
BandWidth 58.89
MACD Line 0.68
MACD Signal Line 1.01
MACD Histogram -0.3222
Fundamentals Value
Market Cap 559.42 Million
Num Shares 49.1 Million
EPS -2.50
Price-to-Earnings (P/E) Ratio -4.56
Price-to-Sales 1000000.00
Price-to-Book 1.84
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.44
Resistance 3 (R3) 13.49 12.87 13.10
Resistance 2 (R2) 12.87 12.35 12.84 12.99
Resistance 1 (R1) 12.13 12.03 11.82 12.08 12.87
Pivot Point 11.51 11.51 11.35 11.48 11.51
Support 1 (S1) 10.77 10.99 10.46 10.72 9.93
Support 2 (S2) 10.15 10.67 10.12 9.81
Support 3 (S3) 9.41 10.15 9.70
Support 4 (S4) 9.36